Purple tea

Purple Tea (Camellia sinensis var. assamica)

1. Identity: Botanical Classification, Source, and Common Forms

Botanical Classification

Purple tea (Camellia sinensis var. assamica) is a distinct variety of Camellia sinensis known for its bioactive compounds, including caffeine, catechins, and a unique compound called 1,2-di-Galloyl-4,6-Hexahydroxydiphenoyl-β-D-Glucose (GHG), found predominantly in purple tea leaves. Camellia sinensis is the botanical name for the tea plant, from which teas such as black, green, white, oolong, purple, and pu-erh teas are produced.

Purple tea is not a distinct type of tea but rather a natural mutation in certain Camellia sinensis var. assamica bushes; its purple leaves can be processed to make white, green, oolong, black, and pu-erh teas. The predominant commercial cultivar is designated TRFK306 (also written TRFK 306/1). Currently, widely cultivated purple tea varieties include TRFK306, Sunrouge, Zijuan, and Ziyan, among others.

Metabolic profiling studies have examined purple-leaf formation in tea cultivars of both Camellia sinensis var. sinensis and var. assamica. The purple-leaf phenotype is mainly attributed to high anthocyanins and low chlorophylls, and also leads to other flavonoid changes including lowered monomeric catechin derivatives and elevated polymerized catechin derivatives.

The Japanese purple-leaf cultivar known as Sun Rouge (サンルージュ) was developed in 2009 by crossing Camellia sinensis var. sinensis with Camellia sinensis var. taliensis, and is typically processed as a green tea.

Color Mechanism

Purple tea comes from the Camellia sinensis Assamica variety, which undergoes a natural mutation that leads to increased levels of anthocyanin pigment. Anthocyanin is responsible for the red, blue, and purple color in flowers, vegetables, and fruits. Like tea polyphenols, anthocyanins belong to the flavonoid group of compounds and are rich in antioxidants. The percentage of anthocyanins in the red or purple tender shoots is 1%–3% of dry weight, which is higher than that in green shoots.

The biosynthesis of these compounds in purple tea exhibits a strong correlation with external environmental factors, encompassing light exposure, temperature fluctuations, and abiotic stressors, resulting in a dynamic profile of flavonoid distribution.

Common Forms and Preparations

Purple tea leaves are processed by the same method used to process green tea. However, the leaves can be used across multiple processing styles. Commercial Kenyan purple tea has been offered in forms including silver needle purple varietal white tea, hand-rolled purple varietal oolong, and steamed purple varietal green tea-style tea.

Purple tea is available commercially in the following forms:

• Loose-leaf tea (steeped as a beverage)
• Standardized dry extracts (capsules and tablets), sold under brand names such as Alluvia and PurpleForce
• Liquid extract concentrations
• Functional food and beverage ingredient (powder, soluble extracts)

When brewed, purple tea produces a beverage whose color can range from pale green to reddish-purple depending on the pH of the water used.

2. Traditional and Historical Use

Plants including Camellia sinensis (tea) have been used as traditional medicines for centuries. In China, India, and various other Eastern and African countries, tea has specifically been used as traditional medicine for diabetes.

Purple tea in its present cultivated form is a recent development and does not possess the long traditional history of use associated with green, black, or white teas. Purple tea is relatively new in the market and is derived from Camellia sinensis var. assamica, which was originally discovered in the Assam region of India. In the late 20th century, Kenyan tea researchers began exploring the potential opportunities for this purple-colored tea leaf.

The history of purple tea begins with the first plant mutation which was observed at the Assam tea gardens in India. The Tea Research Foundation of Kenya (TRFK) then started to research purple tea in the hopes that a variety of the tea plant would have suitable growing conditions there. Its cultivation began in the early 1980s, and finally in 2011, the seedlings were made commercially available to small-scale farmers in Kenya.

As part of a long-term project to diversify the industry that accounts for over a quarter of the country's export earnings and directly or indirectly employs 4 million Kenyans, the state-run Tea Research Institute spent 25 years developing the purple variety, officially named TRFK 306. The TRFK breeders were most interested in creating "a high-value medicinal tea product."

Along with carrying anthocyanin pigments, the TRFK306 hybrid is high-yielding, contains properties to make it resistant to drought, frost, and certain natural pests, and has large leaves making hand-plucking easy. TRFK306/1 has been developed to be higher yielding and more drought resistant, which is very important for Kenyan farmers subject to harsh unpredictable weather patterns.

Kenya now leads as the largest producer of purple tea and is the third-largest producer of commercial tea overall after China and India. This unique tea thrives when grown at high elevations along the equator, where it receives twelve hours of sunlight a day year-round.

It should be noted that while Camellia sinensis broadly has centuries of traditional use across Asian cultures, purple tea as a specific cultivar (TRFK306) is a 20th-century scientific development without an independent traditional medicine heritage. Claims about traditional use of "purple tea" must therefore be understood as largely extrapolated from the traditional use of Camellia sinensis in general.

3. Key Constituents and Active Compounds

Primary Bioactive Compounds

The major constituents in the leaves of purple tea are caffeine, theobromine, epigallocatechin (ECG), epigallocatechin gallate (EGCG), and 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-β-D-glucose (GHG).

In addition to the usual polyphenolic compounds found in green tea, such as EGCG and ECG, purple tea uniquely contains anthocyanidins (malvidin, pelargonidin, and cyanidin 3-O-galactoside) and GHG, a hydrolysable tannin.

In one characterized purple tea extract (PTE) from the Shimoda et al. (2015) study, the principal constituents were found by analysis to be: theobromine (1.6%), caffeine (4.4%), EGCG (9.8%), GHG (7.4%), and ECG (5.8%).

GHG: A Compound Unique to Purple Tea

Purple tea (Camellia sinensis var. assamica) distinguishes itself from other herbal remedies through its unique phytochemical profile, particularly its rich anthocyanin content and the novel polyphenolic compound 1,2-di-Galloyl-4,6-Hexahydroxydiphenoyl-β-D-Glucose (GHG). GHG is classified as a hydrolysable tannin. Purple tea GHG was found to be a better inhibitor of lipase than EGCG, the famous green tea catechin, as shown by research.

Catechins

Catechins are a group of about 30 phenolic compounds, mainly including epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epicatechin (EC). Despite changes in the catechin profile, the overall catechin content remains sufficiently robust, resulting in the distinctive characteristic of purple tea boasting both high anthocyanin and catechin levels, thus enhancing its potential health benefits.

Anthocyanins

Purple tea contains anthocyanidins including malvidin, pelargonidin, and cyanidin 3-O-galactoside, in addition to polyphenolic compounds commonly found in green tea such as EGCG and ECG, and GHG. In addition to anthocyanins, phenolic acids, amino acids, alkaloids, and flavonoids such as flavan-3-ols, proanthocyanins, flavonol, and flavone glycosides are also differentially abundant metabolites in purple tea leaves compared to green tea.

Additional Minor Constituents

Purple tea contains quercetin, kaempferol, and myricetin glycosides. These glycoside compounds contribute to the tea's antioxidant capacity and potential health benefits. It also contains significant amounts of phenolic acids such as gallic, chlorogenic, and p-coumaric acid.

Tea plants contain a unique amino acid called theanine, believed to have cognitive-enhancing and stress-reducing potential. Even though purple tea has lower caffeine content compared to black tea, it still contains caffeine like other teas.

In addition to these principal influential compounds, several minor constituents in purple tea have been explored in limited quantities, including amino acids, organic acids, and a variety of sugars. Numerous studies have consistently reported a substantial reduction in amino acid content in purple tea relative to green tea. Conversely, the concentration of carbohydrates and sugars surpasses that of green-leaf tea by more than twofold.

Caffeine Content Relative to Other Teas

In comparison to green and black tea, purple tea has relatively lesser caffeine content. In analyzed samples, the range of caffeine and theobromine contents were 2.7 to 3.4% and 1.2 to 2.1%, respectively.

4. Mechanisms of Action

Lipase Inhibition and Fat Absorption Reduction

GHG operates through multiple mechanisms, including inhibiting pancreatic lipase to reduce fat absorption, suppressing adipogenesis and lipogenesis, and preventing fatty tissue formation. This effect is probably caused by several components in the purple tea extract, including non-anthocyanin and anthocyanin polyphenols; the former act solely via inhibition of the pancreatic lipase, while the latter inhibit both the lipase and the transport of free fatty acids from the intestinal lumen into the circulating blood.

Enhancement of Hepatic Fat Metabolism (CPT1A)

Protein expression of carnitine palmitoyltransferase (CPT) 1A was enhanced by purple tea extract. The mechanisms of action for green tea's potential role as a weight loss ingredient appear to involve a combination of catechins and caffeine; catechins upregulate hepatic lipid-metabolizing enzymes, including CPT1 to stimulate fat oxidation. GHG appears to replicate and augment this effect.

Alpha-Amylase and Alpha-Glucosidase Inhibition

Purple tea ellagitannins are dual inhibitors of α-amylase and α-glucosidase, and green-purple teas are potent α-glucosidase inhibitors. The bioactive compound GHG is unique to purple tea and has been found to have potent α-amylase inhibitory activity, suggesting potential anti-diabetic effects.

Antioxidant Activity

The antioxidant functionality of purple teas is known to exceed those of its individual parts, indicating a complex interplay among its bioactive constituents. The DPPH and ABTS IC50 value ranges were 25.27–166.47 μg/mL and 10.71–144.21 μg/mL, respectively, for the in vitro antioxidant activity of purple tea extract and isolated anthocyanins. At pH 4.5, anthocyanin-rich purple tea extracts exhibited about 73% inhibition against DPPH radicals, while at pH 10, they showed only about 39%.

The beneficial properties of anthocyanins are largely due to their antioxidant and anti-inflammatory actions. The antioxidant activity depends on their chemical structure, resulting from their high reactivity as hydrogen or electron donors and their ability to chelate transition metal ions via hydroxyl groups.

Anti-Inflammatory Signaling

Current evidence indicates that anthocyanins interact with key signaling pathways such as Nrf2 and NF-κB, and exert effects on oxidative stress, mitochondrial function, vascular homeostasis, and post-exercise adaptation. In both the LPS-activated inflammation model and the prophylactic model, purple-shoot green tea extracts suppressed nitric oxide secretion in a dose-dependent manner, while they also did not enhance IL-6 expression in LPS-stimulated macrophages unlike other teas tested.

AMPK Activation

AMP-activated protein kinase (AMPK) controls lipid metabolism by modulating the CPT-1A and FAS pathways. AMPK activation also correlates with GSK-3β downregulation and mitochondrial biogenesis via PGC-1α. GHG from purple tea has been identified as an AMPK-activating agent in preclinical models; this activation pathway is considered central to the anti-obesity and metabolic effects of the extract.

Blood-Brain Barrier Permeability

A research investigation into the antioxidative potential of Kenyan purple tea extract (PTE) in mice found that PTE significantly increased brain glutathione (GSH) levels, indicating for the first time that PTE from Kenyan purple tea can cross the blood–brain barrier (BBB) and enhance brain antioxidant capacity.

5. Scientific Evidence by Area of Use

5.1 Weight Management and Anti-Obesity

Evidence level: Preliminary — mostly preclinical (animal) and small uncontrolled human trials.

Animal Evidence

Shimoda et al. (2015) investigated the efficacy of purple tea extract (PTE) on diet-induced fat accumulation in mice. PTE administration at 200 mg/kg significantly suppressed body weight gain, liver weight, abdominal fat, and triglycerides in serum and liver. Protein expression of carnitine palmitoyltransferase (CPT) 1A was also enhanced. In olive oil-loaded mice, PTE at 100 mg/kg and caffeine at 25 mg/kg suppressed fat absorption.

In Vitro Evidence

PTE (10 μg/mL) and GHG (10 μg/mL) also enhanced protein expression of CPT1A in HepG2 hepatoma cells.

Human Evidence

In the same Shimoda et al. (2015) study, 4-week daily consumption of a purple tea drink in humans improved obesity parameters compared to baseline, including body weight (79.9 ± 3.1 kg vs 80.8 ± 3.2 kg, p<0.05), body mass index (BMI) (26.8 ± 0.6 vs 27.0 ± 0.6, p<0.05), and body fat mass (21.0 ± 1.4 kg vs 21.8 ± 1.5 kg, p<0.01). The authors concluded that PTE could control diet-induced weight gain by suppression of fat absorption and enhancement of hepatic fat metabolism.

Across clinical investigations reviewed in a 2024 PMC review, significant reductions in BMI, waist circumference, and body weight were demonstrated among individuals consuming purple tea extracts with high GHG levels. Additional metabolic benefits noted include increased energy expenditure, improved insulin sensitivity, and enhanced glucose metabolism regulation.

Limitations: Even if some studies look promising, they are mainly preclinical or small-scale human trials that need wider clinical trials on large groups before determining how effective purple tea is at managing comorbidities associated with excessive weight gain. The 2015 Shimoda et al. human study was conducted without a parallel placebo control group, making causal inference limited. Large-scale randomized controlled trials (RCTs) are lacking as of the available literature.

5.2 Blood Glucose Regulation and Diabetes

Evidence level: Preliminary — in vitro and animal studies; limited human data specific to purple tea.

Camellia sinensis teas were investigated for their anti-diabetic potential, and purple tea was found to be the best inhibitor of both α-amylase and starch absorption in vivo among teas tested. Epigallocatechin gallate is probably involved in the amylase inhibition, and kaempferol and myricetin derivatives may also be involved.

It was concluded that in terms of postprandial anti-hyperglycemic action, purple tea presents the best perspectives among all tea varieties tested in that study.

Purple tea ellagitannins are dual inhibitors of α-amylase and α-glucosidase; green-purple teas are potent α-glucosidase inhibitors; and urolithin A and urolithin B (gut metabolites of ellagitannins) both increase cellular glucose uptake and decrease cellular lipid accumulation.

Several studies have shown that purple tea leaves have potential anti-diabetic properties. The synergistic effects of anthocyanins, catechins, and other polyphenols amplify the tea's metabolic benefits, with research indicating improvements in insulin sensitivity and reduction of inflammatory markers associated with obesity.

Limitations: Most mechanistic data for glucose regulation are from in vitro and animal studies. Direct clinical trial evidence using purple tea specifically for glycemic outcomes in diabetic human populations is lacking.

5.3 Antioxidant Activity

Evidence level: Robust in vitro; animal data supportive; no standalone clinical trials in humans for purple tea antioxidant endpoints.

Purple tea has been widely studied for biological activities including scavenging free radicals, anti-oxidation, anti-cancer, anti-inflammatory, anti-bacterial, protecting eyesight and relieving visual fatigue.

Several therapeutic activities of anthocyanins are mainly contributed by their antioxidant property. Anthocyanins' free radical scavenging property confers a superior antioxidant activity.

The antioxidant functionality of purple teas is known to exceed those of its individual parts, indicating complex interplay among its bioactive constituents. The DPPH and ABTS IC50 value ranges were 25.27–166.47 μg/mL and 10.71–144.21 μg/mL, respectively, for in vitro antioxidant activity of purple tea extract and isolated anthocyanins.

5.4 Neuroprotection

Evidence level: Preliminary — animal studies only; no human RCTs specific to purple tea.

There existed no data on the bioavailability and pharmacological benefits of tea anthocyanins in the brain tissue prior to a key study that investigated the ability of Kenyan purple tea anthocyanins to cross the blood-brain barrier (BBB) and boost brain antioxidant capacity.

Mice were orally administered purified Kenyan purple tea anthocyanins or a combination with coenzyme-Q10 at a dose of 200 mg/kg body weight for 15 days. Brain extracts were analysed by HPLC for anthocyanin metabolites and by spectrophotometry for cellular glutathione (GSH). Kenyan purple tea anthocyanins significantly (p < 0.05) raised brain GSH levels, implying a boost in brain antioxidant capacity.

However, co-administration of both antioxidants (anthocyanins and coenzyme-Q10) caused a reduction of these beneficial effects, implying a negative interaction. Notably, anthocyanin metabolites were detected in brain tissue of anthocyanin-fed mice. These results constitute the first demonstration that Kenyan purple tea anthocyanins can cross the BBB, reinforcing the brain's antioxidant capacity.

Promising evidence is emerging for the procognitive, anti-inflammatory, and neuroprotective properties of dietary flavonoids, particularly anthocyanins. An ongoing multicentre, 6-month randomised, parallel 3-arm clinical trial (the 'Food for Thought' study) has a primary aim of investigating whether anthocyanin consumption, either through diet or supplementation, can prevent memory loss progression and improve inflammatory and cardiovascular health in older adults at risk for dementia. This broader anthocyanin trial is not exclusive to purple tea.

5.5 Cardiovascular Health

Evidence level: Mechanistic and epidemiological for anthocyanins broadly; purple-tea-specific cardiovascular RCTs are not yet established in the literature.

Anthocyanins counteract reactive oxygen species in both the luminal and intimal side, reducing LDL oxidation in vessel walls. During atherogenesis, neutrophil-derived granule proteins stimulate macrophage activation to a proinflammatory state, which can be inhibited by anthocyanins. Both antioxidant and anti-inflammatory effects decrease foam cell formation, and anthocyanins decrease cholesterol by reducing its accumulation in the lipid-rich necrotic core.

A review of clinical studies on the cardioprotective effects of anthocyanins and the role of the gut microbiota in their metabolism suggests anthocyanins have a significant effect on vascular health, though more studies are required to better clarify which molecules and doses show vascular benefits.

Emerging research highlights the potential of purple tea in addressing metabolic health challenges by targeting harmful biomarkers like trimethylamine-N-oxide (TMAO), and its ability to reduce TMAO biomarkers, which are essential to regulate the glucagon-like peptide-1 (GLP-1) receptor.

5.6 Anti-Inflammatory Effects

Evidence level: In vitro and animal model data; no standalone human clinical trials specific to purple tea inflammatory endpoints.

In a prophylactic model, purple-shoot green tea inhibited inflammatory responses by attenuating expressions of IL-6 and TNF-α in a dose-dependent manner. The prophylactic model demonstrated that purple-shoot green tea exerts robust effects on modulating LPS-induced cytokine expressions of MCP-1, IL-6, and TNF-α through scavenging free radicals and NO.

In addition to anthocyanins, phenolic acids, amino acids, alkaloids, and flavonoids such as flavan-3-ols, proanthocyanins, flavonol, and flavone glycosides are differentially abundant metabolites between purple and green tea leaves, each potentially contributing to anti-inflammatory mechanisms.

5.7 Antimicrobial and Anticancer Activity

Evidence level: Preliminary — in vitro only for cancer cell lines; no clinical trial evidence.

Purple tea has been studied for biological activities including anti-cancer and anti-bacterial properties. In addition to catechins, emerging evidence points out that the contents of anthocyanidins and anthocyanins possess not only antioxidant activities but also anti-microbial effects.

Studies on purple tea's anticancer effects have predominantly used isolated anthocyanin-rich extracts against cancer cell lines in vitro. No large-scale human trials examining purple tea specifically for cancer prevention or treatment have been published in the peer-reviewed literature accessible at the time of writing.

6. Body Systems and Health Areas Associated with Purple Tea

• Metabolic / Adipose System: Weight management, fat absorption reduction, lipase inhibition, adipogenesis suppression, BMI and body fat reduction.
• Endocrine / Glycemic System: Alpha-amylase and alpha-glucosidase inhibition, postprandial glucose modulation, insulin sensitivity.
• Hepatic System: Enhancement of hepatic carnitine palmitoyltransferase (CPT1A) expression; modulation of hepatic lipid metabolism.
• Cardiovascular System: LDL oxidation reduction, endothelial function support, TMAO reduction, vascular anti-inflammatory activity.
• Central Nervous System: Blood-brain barrier penetration by anthocyanins, brain antioxidant (GSH) enhancement, neuroprotective potential.
• Immune / Inflammatory System: Suppression of pro-inflammatory cytokines (IL-6, TNF-α, MCP-1), NO scavenging, NF-κB pathway modulation.
• Gastrointestinal System: Enzyme inhibition affecting fat and carbohydrate digestion and absorption.

7. Dosage Forms and Reported Dosages

Even if some studies look promising, they are mainly preclinical or small-scale human trials; more investigations should be made regarding appropriate dosages for these conditions, as well as long-term safety issues.

The following dosages have been used in reported studies:

• Human trial (Shimoda et al., 2015): Purple tea extract at 100 milligrams per day for one month, resulting in significantly decreased levels of subcutaneous fat in the abdomen and upper arms.
• Animal (mouse) studies (Shimoda et al., 2015): PTE administration at 200 mg/kg significantly suppressed body weight gain, liver weight, abdominal fat, and triglycerides in serum and liver. In olive oil-loaded mice, PTE at 100 mg/kg and caffeine at 25 mg/kg suppressed fat absorption.
• Animal (mouse) neuroprotection study: Mice were orally administered purified Kenyan purple tea anthocyanins at a dose of 200 mg/kg body weight for 15 days.
• In vitro: PTE (10 μg/mL) and GHG (10 μg/mL) enhanced CPT1A protein expression in HepG2 hepatoma cells.

The phytochemical profile of purple tea, and by extension its effective constituents, varies according to growing conditions, processing methods, and tea leaf age, which complicates the standardization of dosage across products and preparations.

8. Safety Considerations and Known Interactions

General Safety Profile

Additional research should be conducted to establish an optimal dosage range and long-term safety profile for the use of purple tea. Purple tea contains bioactive molecules as with other teas from Camellia sinensis and thus has potential interactions with medications or supplements consumed alongside it. Although limited data exist concerning interactions involving purple tea specifically, studies on green teas and black teas can provide useful insights.

Polyphenol-Related Interactions

Interactions documented in the broader Camellia sinensis literature include: reduced iron absorption due to polyphenols; possible interference with anticoagulants like warfarin due to vitamin K content; caffeine's propensity to enhance the effects of stimulant medications; the possibility of enhancing antihypertensive and antidiabetic drugs; and possible interactions with tyramine content due to monoamine oxidase inhibitors (MAOIs).

Coenzyme-Q10 Interaction

Co-administration of purple tea anthocyanins and coenzyme-Q10 in a mouse study caused a reduction of beneficial antioxidant effects in the brain, implying a negative interaction between these two antioxidants. This finding has not been replicated in human studies, but warrants attention for supplement users combining these compounds.

Caffeine Content

In comparison to green and black tea, purple tea has relatively lesser caffeine content. However, caffeine-related effects (e.g., insomnia, increased heart rate, interactions with stimulant drugs) remain applicable, particularly in concentrated extract forms.

Anthocyanin Stability

The antioxidant activity of anthocyanin-rich purple tea extracts is pH-dependent; at pH 4.5, extracts exhibited about 73% inhibition against DPPH radicals, while at pH 10, they showed only about 39%. This means that bioavailability and in vivo efficacy may vary with physiological pH conditions in the gastrointestinal tract.

Bioavailability Considerations

Following consumption, anthocyanin absorption occurs along the gastrointestinal tract, with the distal lower bowel being the place where most absorption and metabolism occurs. In the intestine, anthocyanins first undergo extensive microbial catabolism followed by absorption and human phase II metabolism. This means that the bioavailable fraction reaching systemic circulation may differ substantially from the amount ingested.

Evidence Quality Caveat

More comprehensive research is needed to fully elucidate the optimal dosage and long-term effects; current evidence suggests that GHG from purple tea could be a valuable natural intervention in the multifaceted approach to obesity management. Across all health areas reviewed, the evidence base as of 2024–2025 remains early-stage, with most findings coming from in vitro cell culture, animal models, or small uncontrolled human pilot studies. Large, rigorous, placebo-controlled RCTs in human populations are needed before definitive efficacy or safety conclusions can be drawn.

References

• Balasubramaniam AK et al. (2024). Purple Tea (Camellia sinensis var. assamica) Leaves and Obesity Management: A Review of GHG's Potential Health Benefits. Cureus. PMC11698542.
• Shimoda H, Hitoe S, Nakamura S, Matsuda H. (2015). Purple Tea and Its Extract Suppress Diet-induced Fat Accumulation in Mice and Human Subjects. Int J Biomed Sci. PMC4502735.
• Kamil M et al. (2013). Kenyan purple tea anthocyanins ability to cross the blood brain barrier and reinforce brain antioxidant capacity in mice. PubMed PMID 23883519.
• Purple tea: chemical characterization and evaluation as inhibitor of pancreatic lipase and fat digestion in mice. PubMed PMID 36723015.
• Lacroix et al. (2021). The inhibitory action of purple tea on in vivo starch digestion compared to other Camellia sinensis teas. Food Research International. ScienceDirect.
• The potential antidiabetic properties of green and purple tea, purple tea ellagitannins, and urolithins. Journal of Ethnopharmacology. ScienceDirect.
• Zhu MZ et al. (2021). Metabolic Profiling and Gene Expression Analyses of Purple-Leaf Formation in Tea Cultivars. Frontiers in Plant Science. PMC7973281.
• Multiomics analysis of the mechanisms behind flavonoid differences between purple and green tender shoots of Camellia sinensis var. assamica. PMC9911070.
• Advances in Purple Tea Research: Chemical Compositions, Anthocyanin Synthesis and Regulation, Processing, and Health Benefits. Horticulturae (MDPI), 2024.
• Prophylactic Effects of Purple Shoot Green Tea on Cytokine Immunomodulation through Scavenging Free Radicals and NO in LPS-Stimulated Macrophages. PMC9497692.
• Anthocyanin Effects on Vascular and Endothelial Health: Evidence from Clinical Trials and Role of Gut Microbiota Metabolites. PMC10525277.
• Anthocyanins: A Comprehensive Review of Their Chemical Properties and Health Effects on Cardiovascular and Neurodegenerative Diseases. PubMed PMID 32825684.
• Assessing the effect of anthocyanins through diet and supplementation on cognitive function in older adults at risk for dementia: protocol for a randomised controlled trial. PMC11409387.
• Anthocyanin-Rich Purple Plant Foods: Bioavailability, Antioxidant Mechanisms, and Functional Roles in Redox Regulation and Exercise Recovery. PMC12348956.
• Li Y et al. (2021). The Research Progress of Main Chemical Constituents and Functional Activity in Purple Tea. International Journal of Nutrition and Food Sciences.
• Purple Tea, a Rich source of anthocyanin and polyphenol: A Review. Journal of Pharmaceutical Research International.
• How purple tea enhances GLP-1 signaling to support TMAO reduction. NutraIngredients, 2024.
• Tea Tuesdays: Kenyan Farmers See Green In The Color Purple. NPR / The Salt, 2015.
• The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. Frontiers in Pharmacology, 2020.